3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vascular Diseases
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Neoplasms
1
Lung Diseases
1
Embolism and Thrombosis
1
Embolism
1
Disease
1
Cardiovascular Diseases
1
Interventions
Exercise
419
Blood Specimen Collection
319
Standard of Care
299
Surveys and Questionnaires
241
Radiosurgery
239
Magnetic Resonance Spectroscopy
232
Educational Status
223
Methods
221
Radiotherapy
216
Early Intervention, Educational
200
Interviews as Topic
142
Practice Guidelines as Topic
141
Biopsy
125
Surgical Procedures, Operative
119
Drug Therapy
119
Acupuncture Therapy
119
Control Groups
115
Therapeutics
100
Palliative Care
97
Resistance Training
94
Counseling
88
Saline Solution
87
Magnetic Resonance Imaging
84
Cyclophosphamide
83
Specimen Handling
73
Cisplatin
73
Radiofrequency Ablation
71
Cognitive Behavioral Therapy
71
Radiotherapy, Intensity-Modulated
68
Colonoscopy
65
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
OTHER
×
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
×
Clear all
NCT04657120
2025-12-23
HYDRA
Leiden University Medical Center
Phase NA
Completed
698 enrolled